Get the Stockscreener App
0.2791
4.14%
-0.0109
IGC Pharma Inc stock is traded at $0.2791, with a volume of 154.19K.
It is down -4.14% in the last 24 hours and down -12.28% over the past month.
India Globalization Capital, Inc. engages in the development and commercialization of cannabis-based therapies to treat Alzheimer's, pain, nausea, eating disorders, several end points of Parkinson's, and epilepsy in humans, dogs, and cats. The company operates through two segments, Legacy Infrastructure and Medical Cannabis Based Alternative Therapies. The Legacy Infrastructure segment trades in infrastructure commodities, such as steel and iron ore; and rents heavy equipment. The Medical Cannabis Based Alternative Therapies segment offers IGC-501 for indications of neuropathic pain; Serosapse for indications of Parkinson's and other central nervous system disorders; Caesafin for seizures in cats and dogs; and Natrinol for indications of cancer and AIDS induced nausea and vomiting, as well as Hyalolex for Alzheimer's patients. The company was founded in 2005 and is based in Bethesda, Maryland.
See More
Previous Close:
$0.29
Open:
$0.2919
24h Volume:
154.19K
Relative Volume:
0.39
Market Cap:
$19.36M
Revenue:
$1.22M
Net Income/Loss:
$-14.15M
P/E Ratio:
-1.0735
EPS:
-0.26
Net Cash Flow:
$-6.55M
1W Performance:
-2.28%
1M Performance:
-12.28%
6M Performance:
-20.25%
1Y Performance:
-20.57%
1-Day Range:
$0.2753
$0.294
1-Week Range:
$0.2608
$0.295
52-Week Range:
$0.2608
$0.9099
IGC Pharma Inc Stock (IGC) Company Profile
Name
IGC Pharma Inc
Sector
Industry
Phone
301-983-0998
Address
4336 Montgomery Avenue, Bethesda, MD
Compare IGC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IGC
IGC Pharma Inc
|
0.278 | 19.36M | 1.22M | -14.15M | -6.55M | -0.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
488.99 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
688.62 | 75.07B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
634.75 | 37.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.60 | 31.79B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
112.68 | 27.34B | 3.30B | -501.07M | 1.03B | -2.1146 |
IGC Pharma Inc Stock (IGC) Latest News
Ascendiant Capital Markets Issues Positive Forecast for IGC Pharma (NYSEMKT:IGC) Stock Price - Defense World
IGC Pharma expands Holiby line with ‘Longevity’, ‘Renew’ - Yahoo Finance
IGC Pharma Expands Holiby(TM) Product Line With 'Longevity' and - GuruFocus.com
IGC Pharma Expands Holiby(TM) Product Line With 'Longevity' and 'Renew'Targeting the Multi-Billion-Dollar Anti-Aging Market - Newswire
Can IGC Pharma's New Anti-Aging Products Capture a Share of the $182B Wellness Market? - StockTitan
IGC Pharma's Earnings Show Major Turnaround: Net Loss Shrinks 69% While Alzheimer's Drug Shows Promise - StockTitan
IGC Pharma Reports Third Quarter Fiscal 2025 Results - ACCESS Newswire
IGC Pharma, Inc. (IGC) Reports Q3 Loss, Tops Revenue Estimates - MSN
IGC Pharma Inc. (IGC) reports earnings - Quartz
Page 3 | IGC PHARMA INC. DL -,01 Trade Ideas — FWB:IGS1 - TradingView
IGC Pharma Expands Into $75 Billion Wellness Market with the Launch of Holiby(TM) - StreetInsider.com
IGC Pharma launches Holiby wellness brand - TipRanks
IGC Pharma, Inc.: IGC Pharma Expands Into $75 Billion Wellness Market with the Launch of Holiby - finanznachrichten.de
IGC Pharma's Strategic Pivot: New Wellness Brand Holiby™ Taps Into Booming $75B Gummies Market - StockTitan
Market Recap: IGC Pharma Inc (IGC)’s Positive Momentum, Closing at 0.32 - The Dwinnex
Page 3 | IGC PHARMA INC Trade Ideas — TRADEGATE:IGS1 - TradingView
IGC Pharma, Inc. (IGC) Upgraded to Strong Buy: What Does It Mean for the Stock? - MSN
IGC Pharma Named Top 15 Finalist in NIA PREPARE Challenge for AI-Driven Early Detection of Alzheimer's Disease - Joplin Globe
Revolutionary Voice AI Could Detect Alzheimer's Before Symptoms ShowIGC's Breakthrough - StockTitan
IGC Pharma Announces Patient Enrollment at Toronto's Baycrest in Phase 2 Trial Investigating IGC-AD1 - ACCESS Newswire
IGC Pharma Reports Second Quarter Fiscal 2025 Results, Showcasing Progress in Its Alzheimer’s Pipeline - ACCESS Newswire
IGC Pharma Names IGC-AD1 Phase 2 Clinical Trial for Alzheimer's Agitation "CALMA" and Expands Recruitment Strategy - ACCESS Newswire
IGC Pharma Announces Participation in BioPartnering at JPM Alongside the J.P. Morgan 43rd Annual Healthcare Conference 2025 - ACCESS Newswire
IGC Pharma Announces Publication of IMS Spotlight Interview Highlighting Strategic Expansion in Alzheimer’s and Weight Loss Therapies - ACCESS Newswire
IGC Pharma Wins 2 Prizes in Phase 1 of National Institutes of Health's AI PREPARE Challenge - ACCESS Newswire
IGC Pharma to Participate in Fireside Chat with Ascendiant Capital Markets - ACCESS Newswire
IGC Pharma Appoints Former Virginia Governor Terry McAuliffe as Strategic Advisor - Markets Insider
Geode Capital Management LLC Has $240,000 Stock Holdings in IGC Pharma, Inc. (NYSEMKT:IGC) - Defense World
IGC Pharma to Unveil Alzheimer's Pipeline and AI Drug Discovery Updates at Investor Chat - StockTitan
Amazon To Sell Ad Tools To Third Parties - Baystreet.ca
IGC Gains on Word of Alzheimer’s Treatment - Baystreet.ca
IGC Pharma's CALMA Trial Triples Alzheimer's Patient Recruitment with AI-Powered Strategy - StockTitan
IGC Pharma to Present at BIO Partnering @ JPM 2025 Healthcare Conference - StockTitan
What Makes IGC Pharma, Inc. (IGC) a New Buy Stock - MSN
Ascendiant Capital Markets Forecasts Strong Price Appreciation for IGC Pharma (NYSEMKT:IGC) Stock - Defense World
IGC Pharma expands clinical research program for IGC-AD1 - Nasdaq
IGC Pharma Inc Stock (IGC) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.91%
1.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):